| Angiopoietin-like proteins in angiogenesis, inflammation and cancer C Carbone, G Piro, V Merz, F Simionato, R Santoro, C Zecchetto, ... International journal of molecular sciences 19 (2), 431, 2018 | 183 | 2018 |
| Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 R Trovato, A Fiore, S Sartori, S Canè, R Giugno, L Cascione, S Paiella, ... Journal for immunotherapy of cancer 7, 1-16, 2019 | 162 | 2019 |
| HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT F Bruzzese, A Leone, M Rocco, C Carbone, G Piro, M Caraglia, ... Journal of cellular physiology 226 (9), 2378-2390, 2011 | 161 | 2011 |
| Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy A Tamburrino, G Piro, C Carbone, G Tortora, D Melisi Frontiers in pharmacology 4, 56, 2013 | 107 | 2013 |
| PTEN in lung cancer: dealing with the problem, building on new knowledge and turning the game around A Gkountakos, G Sartori, I Falcone, G Piro, L Ciuffreda, C Carbone, ... Cancers 11 (8), 1141, 2019 | 92 | 2019 |
| An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients G Piro, C Carbone, I Cataldo, F Di Nicolantonio, S Giacopuzzi, G Aprile, ... Clinical Cancer Research 22 (24), 6164-6175, 2016 | 76 | 2016 |
| Translational research in the era of precision medicine: where we are and where we will go R De Maria Marchiano, G Di Sante, G Piro, C Carbone, G Tortora, ... Journal of Personalized Medicine 11 (3), 216, 2021 | 70 | 2021 |
| An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis C Carbone, G Piro, M Fassan, A Tamburrino, MM Mina, M Zanotto, ... Oncotarget 6 (15), 13822, 2015 | 63 | 2015 |
| Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells MR Milone, B Pucci, F Bruzzese, C Carbone, G Piro, S Costantini, ... Cell death & disease 4 (5), e641-e641, 2013 | 58 | 2013 |
| A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma G Piro, F Simionato, C Carbone, M Frizziero, G Malleo, S Zanini, ... Oncoimmunology 6 (9), e1322242, 2017 | 56 | 2017 |
| Induction of immunosuppressive functions and NF-κB by FLIP in monocytes A Fiore, S Ugel, F De Sanctis, S Sandri, G Fracasso, R Trovato, S Sartoris, ... Nature Communications 9 (1), 5193, 2018 | 54 | 2018 |
| Lung and gut microbiota as potential hidden driver of immunotherapy efficacy in lung cancer C Carbone, G Piro, V Di Noia, E D’Argento, E Vita, MG Ferrara, S Pilotto, ... Mediators of inflammation 2019 (1), 7652014, 2019 | 51 | 2019 |
| Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase E Di Gennaro, G Piro, MI Chianese, R Franco, A Di Cintio, T Moccia, ... British journal of cancer 103 (11), 1680-1691, 2010 | 50 | 2010 |
| Pancreatic cancer and obesity: molecular mechanisms of cell transformation and chemoresistance P Cascetta, A Cavaliere, G Piro, L Torroni, R Santoro, G Tortora, D Melisi, ... International Journal of Molecular Sciences 19 (11), 3331, 2018 | 49 | 2018 |
| TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy R Santoro, C Carbone, G Piro, PJ Chiao, D Melisi Drug Resistance Updates 33, 36-42, 2017 | 49 | 2017 |
| Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer R Santoro, M Zanotto, F Simionato, C Zecchetto, V Merz, C Cavallini, ... Molecular cancer therapeutics 19 (1), 247-257, 2020 | 45 | 2020 |
| MEKK3 sustains EMT and stemness in pancreatic cancer by regulating YAP and TAZ transcriptional activity R Santoro, M Zanotto, C Carbone, G Piro, G Tortora, D Melisi Anticancer research 38 (4), 1937-1946, 2018 | 44 | 2018 |
| Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients C Carbone, G Piro, F Simionato, F Ligorio, C Cremolini, F Loupakis, G Alì, ... Clinical Cancer Research 23 (15), 4312-4322, 2017 | 43 | 2017 |
| Toll-like receptor 9 agonists for cancer therapy D Melisi, M Frizziero, A Tamburrino, M Zanotto, C Carbone, G Piro, ... Biomedicines 2 (3), 211-228, 2014 | 40 | 2014 |
| Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment C Carbone, A Tamburrino, G Piro, F Boschi, I Cataldo, M Zanotto, ... Anti-cancer drugs 27 (1), 29-40, 2016 | 39 | 2016 |
